...
首页> 外文期刊>Cancer letters >Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion
【24h】

Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion

机译:巨噬细胞衍生的CCL22通过IL-8在恶性胸腔积液中促进免疫抑制肿瘤微环境

获取原文
获取原文并翻译 | 示例

摘要

Immune dysfunction often occurs in malignant pleural effusion (MPE). In our previous study, TGF-beta derived predominantly from macrophages plays an important role in impairing T cell cytotoxicity in MPE. Therefore, we aimed to investigate whether other immunoregulatory cells and factors mediated TGF-beta secretion from macrophages, involved in the immunosuppressive microenvironment of MPE, and to provide clues for potential immune therapy for MPE as well. We found that CCL22 level in MPE was significantly higher than that in nonmalignant pleural effusion. The high level of CCL22 was closely associated with poor survival in MPE patients with lung cancer. CCL22 was dominantly produced by tumor-associated macrophages (TAMs) in MPE. Meanwhile, TAM-derived TGF-beta, mediated CCL22 expression in TAMs via c-Fos. CCL22 promoted the recruitment of regulatory T cells (Tregs) in MPE. Lastly, Treg-secreted high level of IL-8 further induced TGF-beta production from TAMs, and promoted the immunosuppressive tumor microenvironment in MPE. Our results indicate that macrophage-derived CCL22 plays an important role in the immunosuppressive tumor microenvironment via IL-8 in MPE.
机译:免疫功能障碍通常发生恶性胸腔积液(MPE)。在我们以前的研究中,TGF-β主要来自巨噬细胞衍生起到损害MPE中的T细胞细胞毒性的重要作用。因此,我们旨在研究其他免疫调节细胞和因素介导来自巨噬细胞的TGF-β分泌,涉及MPE的免疫抑制微环境,也为MPE提供潜在免疫疗法的线索。我们发现MPE中的CCL22水平明显高于非开始胸腔积液中的水平。高水平的CCL22与MPE患者的肺癌患者存活差异密切相关。 CCL22由MPE中的肿瘤相关的巨噬细胞(TAMS)占主导地位。同时,TAM衍生的TGF-β,通过C-FOS介导的CCL22表达。 CCL22促进了MPE中调节性T细胞(Tregs)的募集。最后,Treg分泌的高水平IL-8进一步诱导从TAMS的TGF-β产生,并促进MPE中的免疫抑制肿瘤微环境。我们的结果表明,巨噬细胞衍生的CCL22在MPE中通过IL-8在免疫抑制肿瘤微环境中起重要作用。

著录项

  • 来源
    《Cancer letters》 |2019年第2019期|共10页
  • 作者单位

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Canc Ctr Zhengzhou 450052 Henan Peoples R China;

    Zhengzhou Univ Affiliated Hosp 1 Biotherapy Ctr Zhengzhou 450052 Henan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    CCL22; IL-8; Macrophage; Malignant pleural effusion; Immunosuppressive tumor microenvironment;

    机译:CCL22;IL-8;巨噬细胞;恶性胸腔积液;免疫抑制肿瘤微环境;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号